XTALPI (02228) saw its stock price surge by 5.08% in intraday trading on Thursday, following the announcement that its incubated company, Signet Therapeutics, has received a prestigious nomination. The company's collaborative drug, SIGX1094R, has been nominated for the 2025 Prix Galien USA Award, often referred to as the "Nobel Prize of Pharmaceuticals," in the "Best Biotechnology Product" category.

This nomination marks a significant milestone for XTALPI and Signet Therapeutics, as SIGX1094R is the world's first targeted therapy for diffuse gastric cancer developed using an "organoid + AI" platform. The drug has already received Orphan Drug Designation and Fast Track Designation from the U.S. FDA and is currently undergoing Phase I clinical trials. This recognition places Signet Therapeutics alongside global pharmaceutical giants such as Amgen, AstraZeneca, Johnson & Johnson, Pfizer, Merck, and Novartis.

The nomination highlights XTALPI's leadership in AI-powered drug discovery and its potential for future growth. As the first "18C stock" and "AI + robotics first stock" on the Hong Kong Stock Exchange, XTALPI's innovative approach to drug development has attracted partnerships with 16 of the world's top 20 pharmaceutical companies. With multiple pipelines in clinical trials and record-breaking collaborations, including a recent HK$47 billion deal with DoveTree, XTALPI's stock surge reflects investor confidence in the company's promising future in the AI pharmaceutical sector.